Skip to main content

Table 3 Multivariable logistic regression models evaluating change in radiographic score (change of 0 or >0) between baseline (< 2 years disease duration) and approximately 36-month disease duration visit in CLEAR I patients (N = 81)

From: Association of anti-peptidyl arginine deiminase antibodies with radiographic severity of rheumatoid arthritis in African Americans

Predictor/variable

Odds ratio (adjusted)a

95 % CI

P value

Multivariable model 1: anti-CCP

 Anti-CCP

2.73

(0.83, 9.0)

0.099

 RA disease duration (per 6 months)

0.90

(0.58, 1.38)

0.618

 Baseline radiographic score (0 referent to >0)

3.91

(1.38, 11.03)

0.010

 Smoking (reference to never smoker)

  Current

0.80

(0.25, 2.49)

0.695

  Former

0.67

(0.18, 2.45)

0.546

Multivariable model 2: anti-PAD4

 Anti-PAD4

0.59

(0.14, 2.51)

0.609

 RA disease duration (per 6 months)

0.87

(0.57, 1.33)

0.526

 Baseline radiographic score (0 referent to >0)

5.41

(1.97, 14.86)

0.001

 Smoking (reference to never smoker)

  Current

0.65

(0.21, 2.10)

0.478

  Former

0.60

(0.17, 2.20)

0.445

Multivariable model 3: anti-PAD4/PAD3

 Anti-PAD4/PAD3

0.21

(0.02, 2.76)

0.235

 RA disease duration (per 6 months)

0.87

(0.57, 1.35)

0.540

 Baseline radiographic score (0 referent to >0)

6.36

(2.22, 18.20)

<0.001

 Smoking (reference to never smoker)

  Current

0.55

(0.18, 1.78)

0.319

  Former

0.51

(0.14, 1.89)

0.313

  1. RA medication and age were not significantly associated with the outcome in the bivariable model and therefore were not included in the multivariable models
  2. aAdjusted for all variables included in the table
  3. CLEAR Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis, CI confidence interval, RA rheumatoid arthritis, PAD peptidyl arginine deiminase enzyme
  4. P values less than 0.05 are shown in bold